A Single-Arm Clinical Study of Autologous Tumor-Infiltrating Lymphocyte Injection (GT307) in the Treatment of Metastatic and Recurrent Advanced Solid Tumors

Summary

This study adopts a single-center, single-arm, open-label design. It aims to evaluate the safety and tolerability of GT307 in patients with advanced solid tumors, as well as assess its pharmacokinetic profile and efficacy, and determine the optimal dosage regimen.

Timeline

Start

2026-04-30

Primary completion

2028-05-31

Completion

2028-05-31

Outcome

Outcome not reported

Stopped: “Due to procedural adjustments at the investigative site, domestic registration on the China health authority's platform must be finalized prior to re-submission on ClinicalTrials.gov. Therefore, we hereby withdraw the current submission.”

Drugs

Indications